Mammotome Announces Acquisition by Leica Biosystems
On October 28, 2014, Devicor® Medical Products, Inc. – makers of the Mammotome® and Neoprobe® families of products, announced an agreement to be acquired by Leica Biosystems, part of the Danaher family of companies. The acquisition is expected to be completed by Q1 2015. This is an exciting step that will help propel the company’s future and allow us to better serve all of our Mammotome and Neoprobe customers and their patients.
Mammotome is the pioneer and global leader in minimally invasive breast biopsy technologies. Leica Biosystems is the global leader in anatomic pathology solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. The combination of our companies uniquely positions us to develop integrated patient-to-pathology solutions for the diagnosis of cancer. Our goal is to improve biopsies and diagnosis for the clinician, pathologists, facility, and patient.
No changes to our product or services
Devicor customers should expect no change in our products or services. Our Sales and Customer Service teams will continue to provide excellent service and support and orders can continue to be placed as usual anywhere in the world. Points of contact, such as Offices, Customer Service, Service & Repair Center and Sales Representatives will remain unchanged.
We believe the combination of best-in-class tissue acquisition, from Mammotome, and anatomic pathology from Leica Biosystems, holds great promise for the future. We will continue to share updates as we move forward with the acquisition.
For more information, please read the Leica Biosystems press release.
If you have any questions or concerns, please do not hesitate to contact us at 1-877-9-A-MAMMO.